The Effects of Cognitive Therapy versus ‘No Intervention’ for Major Depressive Disorder by Jakobsen, Janus Christian et al.
The Effects of Cognitive Therapy versus ‘No Intervention’
for Major Depressive Disorder
Janus Christian Jakobsen
1,2*, Jane Lindschou Hansen
2, Ole Jakob Storebø
1, Erik Simonsen
1, Christian
Gluud
2
1Psychiatric Research Unit, Copenhagen University Hospital and Region Zealand, Roskilde, Denmark, 2Copenhagen Trial Unit, Centre for Clinical Intervention Research,
Department 3344, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
Abstract
Background: Major depressive disorder afflicts an estimated 17% of individuals during their lifetimes at tremendous
suffering and costs. Cognitive therapy may be an effective treatment option for major depressive disorder, but the effects
have only had limited assessment in systematic reviews.
Methods/Principal Findings: We used The Cochrane systematic review methodology with meta-analyses and trial
sequential analyses of randomized trials comparing the effects of cognitive therapy versus ‘no intervention’ for major
depressive disorder. Participants had to be older than 17 years with a primary diagnosis of major depressive disorder to be
eligible. Altogether, we included 12 trials randomizing a total of 669 participants. All 12 trials had high risk of bias. Meta-
analysis on the Hamilton Rating Scale for Depression showed that cognitive therapy significantly reduced depressive
symptoms (four trials; mean difference 23.05 (95% confidence interval (Cl), 25.23 to 20.87; P,0.006)) compared with ‘no
intervention’. Trial sequential analysis could not confirm this result. Meta-analysis on the Beck Depression Inventory showed
that cognitive therapy significantly reduced depressive symptoms (eight trials; mean difference on 24.86 (95% CI 26.44 to
23.28; P=0.00001)). Trial sequential analysis on these data confirmed the result. Only a few trials reported on ‘no remission’,
suicide inclination, suicide attempts, suicides, and adverse events without significant differences between the compared
intervention groups.
Discussion: Cognitive therapy might be an effective treatment for depression measured on Hamilton Rating Scale for
Depression and Beck Depression Inventory, but these outcomes may be overestimated due to risks of systematic errors
(bias) and random errors (play of chance). Furthermore, the effects of cognitive therapy on no remission, suicidality, adverse
events, and quality of life are unclear. There is a need for randomized trials with low risk of bias, low risk of random errors,
and longer follow-up assessing both benefits and harms with clinically relevant outcome measures.
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Introduction
According to the WHO, major depressive disorder is the second
largest healthcare problem worldwide in terms of illness induced
disability [1]. Major depressive disorder afflicts an estimated 17% of
individuals during their lifetimes at tremendous cost to the
individual and society [2,3]. Roughly a third of all depressive
disorders take a chronic course and, compared to other medical
disorders, depressive illnesses causes the most significant deteriora-
tion in individual quality of life [4–6]. Approximately 15% of all
depressive patientswillcommitsuicideovera10–20yearperiod[7].
Antidepressant medication remains the mainstay in the
treatment of depression [8]. However, meta-analyses have shown
that the new antidepressants only obtained beneficial effect in
severely depressed patients, and that this effect seems to be
clinically small [9,10]. Antidepressants are, however, known to
decrease the risk of relapse [11]. The benefits of antidepressant
medication seem to be limited and this raises the question if there
are other effective treatments for this serious illness?
Aaron T. Beck originally developed cognitive therapy for
depression [12]. Beck believed that critical life events could
accentuate hidden negative beliefs, which could generate negative
automatic thoughts. These negative thoughts could lead to
symptoms of depression, which then could reinforce more negative
automatic thoughts. The main goal of the ‘cognitive model of
depression’ is to correct these negative beliefs and thoughts, in
order to treat the depressive symptoms [12]. A recently published
systematic review showed that cognitive therapy might not be an
effective treatment for major depressive disorder compared with
‘treatment as usual’ (different forms of non-specific supportive
interventions) [13]. Another systematic review shows that cognitive
therapy has a preventive effect against recurrent depression, and
that this effect clearly surpasses the preventive effects of
antidepressant medication [14]. Cognitive therapy versus ‘no
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depressive disorder [15]. We have been unable to find any
systematic reviews with meta-analyses, using Cochrane method-
ology, examining the effect of cognitive therapy versus ‘no
intervention’ for major depressive disorder, and the effect size of
cognitive therapy is therefore unclear. We embarked on a
systematic review using Cochrane methodology to assess the effect
of cognitive therapy versus ‘no intervention’ in the treatment of
major depressive disorder [16]. We used assessment of bias risk to
reduce systematic errors, and trial sequential analysis to reduce the
risk of random errors [16–19].
Methods
We conducted our systematic review of randomized clinical
trials involving meta-analysis and trial sequential analysis [16–19]
to answer the question: what are the beneficial and harmful effects
of cognitive therapy versus ‘no intervention’ in the treatment of
major depressive disorder?
For details regarding the methodology please consult our
protocol published on our website (www.ctu.dk) in February 2010,
before we began the systematic literature searches in all relevant
databases, data-extraction, and analyses [20].
In short, we included all randomized clinical trials comparing
the effects of cognitive therapy alone versus ‘no intervention’ alone
or cognitive therapy in combination with any co-intervention
versus ‘no intervention’ in combination with a similar co-
intervention. These co-interventions had to be administered
equally in both intervention groups. We did this because we
wanted to quantify the effect of cognitive therapy versus ‘no
intervention’. No intervention encompassed all potential interven-
tions, including medical treatments; talk therapy; psychology; etc.-
except ‘waiting list’. The trials were included irrespective of
language, publication status, publication year, and publication
type - based on searches in The Cochrane Library’s CENTRAL,
MEDLINE via PubMed, EMBASE, Psychlit, PsycInfo, and
Science Citation Index Expanded (Figure S1. The timeframe for
the search was all trials published before February 2010.
To be included, participants had to be older than 17 years with
a primary diagnosis of major depressive disorder. Trials were only
included if the diagnosis of depression was based on one of the
standardized criteria, such as ICD 10 [21], DSM III [22], DSM
III-R [23], or DSM IV [24]. Comorbidity with other psychiatric
diagnoses was not an exclusion criterion. The following types of
trials were excluded:
N Trials focusing on depressed participants with comorbid
serious somatic illness, e.g., myocardial infarction, multiple
sclerosis, cerebral stroke, cancer, etc.
N Trials focusing on ‘late life’ depression or depression in the
elderly, most often participants over 65 years.
N Trials focusing on pregnancy related depression, e.g., postpar-
tum depression, postnatal depression, etc.
N Drug or alcohol dependence related depression.
These exclusions were conducted because we expect partici-
pants in such trials to respond differently to standardized
psychotherapy than other depressed patients, and these types of
depressed patients are traditionally examined in separate trials
[25–28].
Interventions
Cognitive therapy. Cognitive therapy and cognitive-
behavioral therapy are collective terms for a range of different
forms of interventions, and it is difficult to find a simple definition
which adequately describes this psychotherapeutic method.
However, we selected the following criteria from Beck as being
necessary for the intervention to be classified as ‘cognitive therapy’
[12]:
1. That the intervention sought to link thoughts, feelings, and
behavior, and related these to the depressive symptoms.
2. That the intervention sought to record and correct irrational
thoughts or behavioral patterns, and related these to the
depressive symptoms.
3. That the intervention sought to teach the patient alternative
methods of thinking or behaving, and related these to the
depressive symptoms.
4. That the intervention was undertaken face-to-face either
individually or in a group.
We accepted any co-intervention to cognitive therapy as long as
this co-intervention was similar and administered equally to the
experimental group (cognitive therapy) and the control group (‘no
intervention’). As mentioned in the introduction, this was done
because we wanted to quantify the effect of cognitive therapy.
Furthermore, the trials had to present a treatment manual and
had to documentadherenceto the treatment manual inorder for the
intervention to be classified as ‘cognitive therapy, adequately
defined’.Allothertrialsthatclassifiedtheirinterventionas‘cognitive’
or ‘cognitive-behavioral’ were included, but the intervention was
classified under ‘cognitive therapy, not adequately defined’.
Trial selection
Three of the review authors (JJ, OJS, and JLH) independently
selected relevant trials. If a trial was selected by three or two of the
three, it was included. If a trial only was identified only by one of
the three, it was discussed whether the trial should be included.
Excluded trials were entered on a list, stating the reason for
exclusion.
Data extraction
Data were extracted for trial design, bias risk, and outcomes
independently by two authors (JJ and JLH). Disagreements were
resolved by discussion or through arbitration (CG). We used the
instructions in The Cochrane Handbook for Systematic Reviews of
Interventions in our evaluation of the methodology and hence bias
risk of the trials [16]. We assessed the bias risk in respect to
generation of the allocation sequence; allocation concealment;
blinding; intention-to-treat analysis; drop-outs; reporting of out-
come measures; economic bias; and academic bias. Economic bias
may be present if a trial is financed by an individual or organisation
that might have an interest in a given result from the trial [16].
Aqcademic bias may be present if one or more of the trialists have
an academic or personal interest in a given result from the trial [16].
These components enable classification of the included trials into
trials with ‘low risk of bias’ or with ‘high risk of bias’. The trials were
overall classified as ‘high risk of bias’ if one or more of the above
components was ‘uncertain’ or ‘high risk of bias’ [16,29–32]. This
classification is important because trials with ‘high risk of bias’ may
overestimate positive intervention effects and underestimate
negative intervention effects, and we wanted to relate the validity
of our results to the risk of bias in the included trials [16,29–32].
Primary outcomes
Depressive symptoms. Our primary outcomes were the
mean value of Hamilton Rating Scale for Depression (HDRS)
Cognitive Therapy for Depression
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Asberg Depression Rating Scale (MADRS) [35] at follow-up. We
included data based on the total number of randomized patients
(intention-to-treat analysis) if these data were reported. We
planned to estimate the therapeutic follow-up responses at two
time points:
N At cessation of treatment: The trials’ original primary choice of
completion date was used. This was the most important
outcome measure time point in this review.
N At maximum follow-up.
Adverse events. We classified adverse events as serious or
non-serious. Serious adverse events were defined as medical events
that are life threatening; result in death; disability or significant loss
of function; that cause hospital admission or prolonged
hospitalization; a hereditary anomaly; or fetal injury [36]. All
other adverse events (that is, events that have not necessarily had a
causal relationship with the treatment, but that resulted in a
change in- or cessation of the treatment) were considered as non-
serious events.
Quality of life. We included any measure of quality of life
noting each assessment measure.
Secondary outcomes
The proportion of patients not having achieved remission was
our first secondary outcome. We included data based on the total
number of randomized participants (intention-to-treat analysis) - if
possible. If the results were not based on the total number of
participants, we preformed an intention-to-treat analysis assuming
that the participants not included in the results did not achieve
remission [16]. We pragmatically defined remission as a HDRS of
less than 8, BDI less than 10, or MADRS less than 10 [34–36].
These definitions are also the most commonly used.
Records of suicide inclination, suicide attempts, or suicides were
other secondary outcomes.
Statistical methods
This meta-analysis was undertaken according to the recom-
mendations stated in The Cochrane Handbook for Systematic
Reviews of Interventions [16]. In analyzing continuous outcomes
with both fixed-effect and with random-effects models, we used the
mean difference (MD) with a 95% confidence interval. For
statistical calculations we used RevMan version 5.0 [37]. We did
not use ‘standardized mean difference’ so each outcome measure
was analyzed separately. We did not adjust the outcome variables
at follow-up according to the baseline values [16].
We used the odds ratio with a 95% confidence interval to
estimate intervention effects on dichotomous outcomes with both
fixed-effect and with random-effects models [37].
We performed ‘test of interaction’ [38] for all subgroup analyses
[20].
For the primary outcome measure and significant secondary
outcome measure, we also conducted trial sequential analysis [39].
In order to calculate the required information size and the
cumulative Z-curve’s eventual breach of relevant trial sequential
monitoring boundaries [16–19], the required information size for
continuous outcomes was based on a type I error of 5%, a beta of
10% (power of 90%), the variance of all the trials (as no trial had
low risk of bias), and a minimal relevant difference of 2 points on
the HDRS. For dichotomous outcomes, we based the control
proportion on our meta-analytic findings, an assumed relative risk
reduction of 30%, a type I error of 5%, a beta of 10% (power of
90%), and the heterogeneity in the meta-analysis.
Results
Search results
Our primary literature search identified 4536 publications.
According to our protocol [20] we excluded 4137 publications on
the basis of the title or abstract, and further 339 citable units were
excluded on the basis of the full publication. These exclusions were
done either because the publications did not relate to cognitive
therapy and depression, or because they were not randomized
trials comparing cognitive therapy versus ‘no intervention’.
Further 41 publications were excluded because the trial partici-
pants or the interventions did not meet our inclusion criteria.
Included trials
We identified and included 19 publications [40–58] on 12 trials
[40–43,46–51,53,55] randomizing a total of 669 participants
(Figure S2).
Only six of the trials [40–43,47,50] used an intervention that we
classified as ‘adequately defined’ (see above). We classified the
therapists’ level of experience and/or education in two trials as
‘high’ [49,55], in two trials as ‘intermediate’ [46,50], in one trials as
‘low’ [40], and in the last seven as ‘unclear’ [41–43,47,48,51,53].
Three trials used cognitive group therapy [40,42,51], one trial used
a combination of group and individual therapy [53], the remaining
eight trials used only individual therapy [41,43,46–50,55].
The duration and the extent of the therapy varied in the
different trials from six weekly 30 minute sessions of treatment
[47] to 24 weeks of treatment (five times a week during the
inpatient stay and weekly during the outpatient phase) [55].
Eight trials used the experimental intervention cognitive therapy
as add on therapy to antidepressant medicine [46–51,53,55]. All of
the eight trials used different antidepressants (Figure 1). The
antidepressant medicine was delivered similarly in the experimen-
tal and control groups in all of the trials.
Blackburn et al. (1981) examined the effect of cognitive therapy
and antidepressants versus antidepressants [51]. The participants
were assessed with HDRS and BDI. The results at the end of
treatment show a significant effect of cognitive therapy compared
with the control. However, the trial did not report SD for the
mean values.
Teasdale et al. (1984) examined the effect of cognitive therapy
and ‘treatment as usual’ versus ‘treatment as usual’ [41]. The
participants were assessed with HDRS, BDI and MADRS.
However, the results were only reported as median values.
Participants receiving cognitive therapy had improved significantly
greater than the control group on all three scales at cessation of
treatment. There was no significant difference at three months
follow-up.
Usaf et al. (1990) examined the effect of cognitive therapy versus
‘waiting list’ [42]. The participants were assessed with BDI.
Participants receiving cognitive therapy had a non-significant
greater improvement on outcome measures compared with
control. However, the trial did not report SD for the mean values
Wright et al. (2005) examined the effect of cognitive therapy
versus ‘waiting list’ [43]. The participants were assessed with
HDRS and BDI. The results at end of treatment showed a
significant effect of cognitive therapy compared with control.
However, the trial did not report mean values and SD. The
authors chose to report change in scores instead of mean on
continuous outcome, because the baseline-means were significant-
ly different between the two intervention groups.
We have written to the authors of the four trials in the above
[41–43,51] requesting the necessary data. We have received no
Cognitive Therapy for Depression
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four trials in the following analysis.
Table 1 summarizes the characteristics of the 12 included trials.
Bias risk
We assessed all of the 12 included trials [40–43,46–51,53,55] as
having ‘high risk of bias’ due to unclear or inadequate components
as described in Table 2.
Primary outcome measures
Depressive symptoms. Four trials assessed and reported
HDRS as a continuous outcome measure at the end of treatment
[46,47,49,50]. Eight trials also assessed and reported BDI [40,46–
50,53,55].
Meta-analysis with the fixed-effect model on the HDRS data
from the four trials [46,47,49,50], shows that cognitive therapy at
the end of therapy significantly reduced depressive symptoms
compared with ‘no intervention’. We found a mean difference on
23.05 HDRS (95% CI 25.23 to 20.87; P,0.006, I
2=0)
(Figure 1). The I
2 statistic describes the percentage of variation
across trials that are due to heterogeneity rather than chance.
Meta-analysis with the random-effects model gave identical results.
Meta-analysis with the fixed-effect model on the BDI data from
the eight trials [40,46–50,53,55] was in agreement with the results
from HDRS (mean difference on 24.86 BDI (95% CI 26.44 to
23.28; P=0.00001, I
2=0)) (Figure 2). Meta-analysis with the
random-effects gave identical results.
Trial sequential analysis on the HDRS data showed that
‘insufficient data’ have been obtained to decide if cognitive therapy
is superior compared with ‘no intervention’ (Figure 3). Trial
sequential analysis on the BDI data showed a significant beneficial
effectofcognitivetherapycomparedwith‘nointervention’(Figure4).
Only two of the trials included assessment data after the
cessation of treatment on the HRDS [46,47]. Murphy et al. (1984)
assessed the participants at one month after cessation of treatment
and Scott et al. (1997) at one year after cessation of treatment
[46,47]. Meta-analysis with fixed-effect model on these data
showed a mean difference on 20.32 HDRS points (95% CI 20.85
to 20.22; P=0.25, I
2=57%) and 23.68 BDI points (95% CI
28.11 to 20.75; P=0.10, I
2=0) in favor of cognitive therapy.
Meta-analysis with random-effects gave an identical result.
Adverse events. Two trials reported adverse events [40,50].
Hollon et al. (1992) reported five serious adverse events in the
control group (two participants hospitalized due to symptomatic
worsening and three experiencing severe adverse reactions to
concomitant medications) [50]. Wong et al. (2008) reported one
hospitalization in the control group [40]. None of the remaining
trials reported on adverse events.
Quality of life. None of the included trials assessed the
quality of life of the participants.
Secondary outcome measures
Participants without remission. Three trials reported the
proportion of participants without remission as a dichotomous
outcome measure [46,50,55]. We had planned to define remission
as a Hamilton score of less than 8, BDI less than 10, or MADRS
less than 10. However, this was not possible, so we adopted the
slightly different definitions of the individual trials. All three trials
defined remission as HRDS less than 7 [46,50,55], while one trial
also defined remission as a Hamilton score of less than 8 [46]. All
three trials also defined remission as BDI less than 10 [46,50,55].
Meta-analysis on the HDRS data from the three trials
[46,50,55] showed that cognitive therapy compared with ‘no
intervention’ significantly decreases the risk of ‘no remission’ with
an odds ratio of 0.42 (95% CI, 0.21 to 0.85; P=0.02, I
2=0)
(Figure 5). The number needed to treat to obtain one extra patient
with remission is about four patients (95% CI, 3 to 13). Trial
sequential analysis on these data shows that we cannot exclude risk
of random errors due to sparse data and repetitive testing as the
cause for the meta-analysis result (Figure 6).
The meta-analysis on the BDI-data from the three trials
[46,50,55] showed that cognitive therapy compared with ‘no
intervention’ did not significantly decrease the risk of ‘no
remission’ with an odds ratio of 0.54 (95% CI, 0.27 to 1.09;
P=0.08, I
2=0).
Participants with suicidal inclination. Teasdale et al.
(1984) reported numbers of patients that deliberate self-poisoned
[41]. No patient in the cognitive therapy group self-poisoned. Two
of the patients in the control group were treated for deliberate self-
poisoning.
Miller et al. (1989) trial used the Modified Scale for Suicidal
Ideation [55]. They found no significant difference in suicidal
ideation between the different intervention groups, and recorded
no suicide attempts or suicides during the trial period.
Hollon et al. (1992) reported three suicide attempts [50], one
participant randomized to cognitive therapy and two participants
randomized to the control intervention. One from each group died
from their attempt.
Figure 1. The effect of cognitive therapy versus ‘no intervention’ at cessation of treatment on Hamilton Rating Scale for Depression
(HDRS). Below figure: All four trials used only individual cognitive therapy. The therapists’ level of experience and/or education was classified as
‘high’ in Dozios (2009), as ‘intermediate’ in Murphy (1984) and Hollon (1992), and as ‘unclear’ in Scott (1997).
doi:10.1371/journal.pone.0028299.g001
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Trial Particiants (randomized) Interventions Outcomes and notes
Blackburn 1981 42 Cognitive therapy (individual, 20 weeks)+150 mg
amitriptyline or 150 mg clomipramine
HDRS, BDI
No means or SD
Murphy 1984 46 Cognitive therapy (individual, 12 weeks)+nortriptyline
(TCA) versus nortriptyline (TCA) dose of nortriptyline:
50 to 150 ng in venous blood
HDRS, BDI, remission (HDRS,8,
HDRS,7) and BDI,10)
Teasdale 1984 44 Cognitive therapy (individual, 20 sessions)+‘treatment
as usual’ versus ‘treatment as usual’
‘treatment as usual’: general practitioners were
asked to treat patients as they would normally
HDRS, BDI and MADRS.
No means and SD (report median scores)
Ross 1985 67 Cognitive therapy (individual and group, 12 weeks)+
‘treatment as usual’ versus waiting list+‘treatment as usual’
‘treatment as usual’: treatment by the referring GP
including different antidepressants
BDI and Montgomery- Asberg scale.
10/67 of the participants had only
‘probable major depressive disorder
Miller 1989 32 Cognitive therapy (5 weekly individual sessions for 4
weeks followed by 1 weekly session for 20 weeks)+
‘standard treatment’ versus ‘standard treatment’
‘standard treatment’ included use of antidepressants
(amitriptyline and desipramine)
BDI, Modified HDRS Scale for Suicidal
Ideation and remission (BDI,10,
HDRS,7)
Participants were inpatients
Usaf 1990 60 Cognitive therapy (group, 8 weeks) versus ‘waiting list’ BDI.
No means or SD
Hollon 1992 82 Cognitive therapy (individual, 12 weeks)+75–300 mg
imipramine versus 75–300 mg imipramine
HDRS, BDI, Raskin Depression Scale and
remission (HDRS,7, BDI,10)
Scott 1997 48 Cognitive therapy (individual, 6 weeks)+‘treatment as usual’
versus ‘treatment as usual’
‘treatment as usual’: treatment by GP including different
antidepressants
HDRS and BDI
Wright 2005 30 Cognitive therapy (individual, 8 weeks) versus ‘waiting list’ HDRS and BDI.
No SD
Shamsaei 2008 80 Cognitive therapy (individual, 8 weeks)+citalopram
(SSRI) versus citalopram (SSRI)
BDI
Wong 2008 96 Cognitive therapy (group, 10 weeks) versus waiting list BDI (Chinese BDI)
Dozois 2009 42 Cognitive therapy (individual, 15 weeks)+antidepressants
versus antidepressants antidepressants: SSRI, SNRI and TCA
HDRS, BDI
doi:10.1371/journal.pone.0028299.t001
Table 2. Risk of bias.
Allocation
sequence
generation?
Allocation
concealment?
Intention
to treat
analysis? Blinding?
Comparability
of drop-outs in
intervention
groups?
Free of
selective
outcome
measure
reporting?
Free of
economic
bias?
Free of
academic
bias?
Overall bias
assessment
Blackburn 1981 Unclear Unclear No Unclear Yes Unclear Unclear Unclear High risk of bias
Murphy 1984 Yes No Yes No Unclear Unclear Yes Unclear High risk of bias
Teasdale 1974 Unclear Unclear No Yes No Unclear Yes Unclear High risk of bias
Ross 1985 Yes Unclear Yes Yes Unclear Unclear Unclear Unclear High risk of bias
Miller 1989 Unclear Unclear No No Yes Unclear Unclear Unclear High risk of bias
Usaf 1990 Unclear Unclear No No No Unclear Unclear Unclear High risk of bias
Hollon 1992 Unclear Unclear No Yes Yes Unclear Unclear Unclear High risk of bias
Scott 1997 Unclear Unclear No Unclear No Unclear Yes Unclear High risk of bias
Wright 2005 Unclear Unclear Yes Yes Yes Unclear Unclear Unclear High risk of bias
Shamsaei 2008 Yes Unclear Unclear Unclear Unclear Unclear Yes Unclear High risk of bias
Wong 2008 No Unclear Unclear Unclear No Unclear Unclear Unclear High risk of bias
Dozois 2009 Unclear Unclear No Unclear Yes Unclear Unclear Unclear High risk of bias
doi:10.1371/journal.pone.0028299.t002
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doi:10.1371/journal.pone.0028299.g002
Figure 3. Trial sequential analysis of the cumulative meta-analysis of the effect of cognitive therapy versus ‘no intervention’ for
major depressive disorder on the Hamilton Rating Scale for Depression (HDRS). Below figure: The required information size of 994 is
calculated based on an intervention effect compared with ‘no intervention’, of 2 points on the HDRS, a variance of 126.5.04 on the mean difference, a
risk of type I error of 5%, and a power of 80%. With these presumptions, the cumulated Z-curve (blue curve) do not cross the trial sequential
monitoring boundaries (red inner sloping lines) implying that there is no firm evidence for a beneficial effect of cognitive therapy compared with no
intervention.
doi:10.1371/journal.pone.0028299.g003
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therapy group and two suicide attempts in the control group
during the intervention period [40]. Neither of these participants
died from their attempt.
None of the remaining trials included records of suicide
inclination, suicide attempts, or suicides.
Subgroup analyses
According to our protocol [20] we had planned a number of
subgroup analyzes, but we found no heterogeneity in our results.
We therefore did not conduct subgroup analyses of therapists’ level
of education and experience (high versus intermediate versus low
versus unclear), type of therapy (group versus individual), and use
Figure 4. Trial sequential analysis of the cumulative meta-analysis of the effect of cognitive therapy versus no ‘intervention’ for
major depressive disorder on the Beck Depression Inventory (BDI). Below figure: The required information size of 570 is calculated based on
an intervention effect compared with ‘no intervention’, of 4 points on the BDI, a variance of 153.1 on the mean difference, a risk of type I error of 1%
and a power of 90%. With these presumptions, the cumulated Z-curve (blue curve) crosses the trial sequential monitoring boundaries (red inner
sloping lines) implying that there is no risk of random error in the estimate of a beneficial effect of cognitive therapy compared with no intervention.
However, all trials were considered as high risk of bias, which could explain the positive findings.
doi:10.1371/journal.pone.0028299.g004
Figure 5. Effect of cognitive therapy versus ‘no intervention’ on ‘no remission’ (HDRS.7) at cessation of treatment.
doi:10.1371/journal.pone.0028299.g005
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tion versus no antidepressant co-intervention). Our findings
indicate that these factors do not seem to influence the effect of
cognitive therapy.
We had also planned a subgroup-analysis according to risk of
bias [20]. However, as all trials were classified as ‘high risk of bias’
it was not possible to conduct this analysis.
Discussion
The results of our systematic review with meta-analysis and trial
sequential analysis (on the BDI-data) suggest that cognitive therapy
may significantly reduce depressive symptoms on the HDRS and
BDI, and may increase the probability of remission compared with
‘no intervention’. The number needed to treat to obtain one extra
patient with remission is about four patients (95% CI, 3 to 13), but
trial sequential analysis suggests that this result could be due to
random error due to sparse data or repetitive testing (NY ref).
When evaluating these data, one should notice that all trials were
considered to have high risks of bias which could lead to
overestimation of beneficial intervention effects.
The present review has a number of strengths. Our protocol
[20] was published before we began systematic literature searches
in all relevant databases, data extraction, and data analysis. Data
was extracted by two independent authors minimizing the risk of
inaccurate data-extraction, and we assessed the risk of bias in all
trials according to the Cochrane Handbook for Systematic
Reviews of Interventions [16]. We meta-analyzed data both with
fixed-effect and random-effects models and both analyses were in
agreement in all our results. Furthermore, we performed trial
sequential analysis to assess the risk of random errors [16–19]. The
results of the trial sequential analysis on the BDI data confirmed
the cumulative meta-analysis result. Trial sequential analysis on
the HDRS data showed that insufficient data have been obtained,
but this analysis was based on the results from only four trials. The
trial sequential analysis result also indicates that in order to detect
or reject an intervention effect with a minimal relevant difference
of two points on HDRS, a required information size of 994
Figure 6. Trial sequential analysis of the cumulative meta-analysis of the effect of cognitive therapy versus no ‘intervention’ for no
remission according to the Hamilton Rating Scale for Depression. Below figure: The required information size of 303 is calculated based on a
control event proportion of 62%, an assumed relative risk reduction of 30%, a type I error of 5%, a beta of 10% (power of 90%), and the heterogeneity
in the meta-analysis. With these presumptions, the cumulated Z-curve (blue curve) do not cross the trial sequential monitoring boundaries (red inner
sloping lines) implying that there is a risk of random error in the estimate of a beneficial effect of cognitive therapy compared with no intervention,
either due to sparse data or repetitive testing in the cumulative meta-analysis. Furthermore, all trials were considered as high risk of bias, which could
explain the positive findings in the conventional meta-analysis.
doi:10.1371/journal.pone.0028299.g006
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trials and trial participants and with an increasing number of
repetitive tests, the risk of falsely rejecting the null hypothesis (type
I error) is substantial Trial sequential analysis is a statistical
analysis that enables one to assess the risks of random errors that
may occur due to sparse data and multiple testing on accumulating
data. Trial sequential analysis is therefore a more robust analysis
than the traditional cumulative meta-analysis [16–19].
Our systematic review has a number of limitations. The
characteristics of the participants in the different trials, as well as
the severity of the depressive symptoms differed. E.g., the
participants in Miller et al. (1989) were inpatients and Scott et
al. (1997) examined the effect of cognitive therapy for depression
in primary care patients [47,55]. Nine [41,46–51,53,55] of the 12
included trials used some form of antidepressants as co-
intervention to cognitive therapy. We did not, however, find any
heterogeneity in our analyses and although head-to-head com-
parisons are needed in order to thoroughly examine differences
between intervention groups, this indicates that there is a
comparable treatment effect regardless of the use of antidepres-
sants as co-intervention and among the different populations
treated. This may make our results more generally applicable. On
the other hand, only few trials with few participants were included,
which may decrease the external validity of our results.
The fact that we were only able to include 12 trials with a
limited number of participants also raises other concerns. Only
four of the 12 trials reported mean and SD for HDRS, and only 8
of the 12 trials reported means and SD for BDI. None of the
included trials were assessed as being free of ‘selective outcome
measure reporting bias’ [16]. There is therefore a risk of within-
study selective outcome reporting in the 12 trials. Furthermore, all
12 trials had an overall assessment as ‘high risk of bias’ - so our
results may be questionable. Moreover, trial sequential analysis on
the effect on HDRS showed that we could not exclude the risk of
random errors [16–19]. Due to the limited number of included
trials we did not perform a funnel plot or other analysis to explore
the risk of publication bias [16]. Other meta-analyses have shown
that publication bias significantly has influenced the results from
former publications [9]. It is a further limitation that we are not
able to assess the risk of publication bias.
Only six of the trials used an intervention that we classified as
‘adequately defined’, i.e., using and documenting the use of a
therapeutic manual. And although we did not find any
heterogeneity in our results it is imperative in clinical trials that
the interventions are adequately defined and described [59].
Factors like personal style, communication skills, and personality
of the therapist evidently will influence the way psychotherapy is
delivered [60], and it is difficult to describe and control for these
subjective factors. It is therefore important to relate psychother-
apeutic interventions to a treatment manual. Otherwise it is
unclear what kind of intervention the participants were receiving,
and it is difficult to apply any result in clinical practice.
A number of subgroups of depressed patients were not included
in the trials of this review. These subgroups may react differently
to psychotherapy and of course our review cannot be generalized
to other than the included patient groups.
Because we wanted to quantify the effect of cognitive therapy,
any co-intervention had to be delivered similarly in the
experimental intervention group and the control group. So forth,
our results show that the benefit from this relatively extensive
treatment compared with ‘no intervention’ was only a few points
on HDRS and BDI. We believe that these mean differences are
relatively small from a clinical viewpoint - especially if you relate
these mean differences to the extent and length of the intervention.
On the other hand, our analyses demonstrate that the number
needed to treat to obtain one extra patient in remission was only
about four patients. This estimate was based on only three trials,
which primarily defined remission as a HDRS or a BDI score
under a given value. Again, we are not able to exclude the risks of
systematic errors (bias) and random errors (play of chance) on this
estimate.
Depression is generally a difficult condition to treat effectively
and other reviews have found similar effects for other forms of
psychotherapy [61]. However, the HDRS might not be a useful
instrument to quantify the effect of cognitive therapy. Other
assessment methods could demonstrate a more substantial effect of
any given intervention for depression. Furthermore, severity of
depression as measured by the total HDRS score has failed to
predict suicide attempts [62], and some publications have
questioned the usefulness of the HDRS and concluded that the
scale is psychometrically and conceptually flawed [63]. The two
other outcome measures often used to assess depressive symptoms,
MADRS and BDI, probably correspond to HDRS [64,65]. The
HDRS has during 40 years been the gold standard to quantify
depressive symptoms in clinical trials [63]. There may be a need
for other assessment methods.
Only two of the trials included assessments after the cessation of
treatment. Therefore it is not clear whether cognitive therapy has
any effect on depressive symptoms in the longer term.
None of the trials reported measures of quality of life. Outcome
measures of quality of life are generally not standardized and
thoroughly individually validated [69]. The use of standardized
outcome measures for quality of life in research has been limited
by difficulties in administering and scoring quality of life, but
quality of life can be used as a valid outcome measure [31,66].
Only two of the included trials reported on some adverse events
and only four of the included trials included some records of
suicide inclination, suicide attempts, or suicides. Typically adverse
events are not reported as thoroughly as beneficial outcome
measures [67]. Some psychological interventions might have
harmful effects. E.g., psychological debriefing for preventing post-
traumatic stress disorder has in some clinical trials showed to have
a harmful effect [68]. Possible harmful effects of cognitive therapy
are not thoroughly examined.
Future research should focus on comparing different forms of
manualized psychotherapy and comparing cognitive therapy with
other treatments for depression. First and foremost such trials
should be conducted with lower risk of bias (‘systematic errors’)
and lower risk of random errors (‘play of chance’) as well as longer
follow up [69]. Such trials should also report on adverse events,
suicide inclination, suicide attempts, and numbers of suicides.
There may also be a need for a new gold standard assessment
method other than HRDS to assess depressive symptoms, and if
possible more effective interventions for depression must be
developed. But first and foremost trials with lower risk of bias
and lower risk of random errors are needed.
Conclusions
Cognitive therapy might be an effective treatment for
depression measured on HDRS and BDI, but the effects on
suicidality, adverse events, and quality of life are unclear. There is
a need for randomized trials with low risk of bias, low risk of
random errors, and longer follow-up assessing both benefits and
harms with clinically relevant outcome measures.
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